In this regard, withaferin A and altretamine (FDA-approved drugs for cancer therapy), with function to inhibit GPX4, exhibited favorable anti-tumor activity in animal models, representing another option for targeting GPX4 in vivo (Woo et al., 2015; Hassannia et al., 2018). Here, GPX4 is linked to cancer.